Showing 7371-7380 of 20412 results for "".
The NASH Epidemic: Highlights from the AMCP 2023 Symposium
https://reachmd.com/programs/cme/the-nash-epidemic-highlights-from-the-amcp-2023-symposium/14957/Tune in to hear key takeaways and a breakdown of clinical data from a recent satellite symposium focused on the screening and treatment NASH.What’s Next for TROP2-Directed ADCs in TNBC?
https://reachmd.com/programs/cme/current-unmet-needs-in-first-line-treatment-of-metastatic-tnbc/60636/Explore how first-line TROP2-directed ADCs are reshaping metastatic TNBC care, with evidence-based treatment selection and proactive toxicity management.Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
https://reachmd.com/programs/cme/translating-evidence-on-trop2-directed-adcs-into-global-practice-in-metastatic-tnbc/60637/Explore how first-line TROP2-directed ADCs are reshaping metastatic TNBC care, with evidence-based treatment selection and proactive toxicity management.Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
https://reachmd.com/programs/cme/managing-adverse-events-associated-with-trop2-directed-adcs-in-metastatic-tnbc/60635/Explore how first-line TROP2-directed ADCs are reshaping metastatic TNBC care, with evidence-based treatment selection and proactive toxicity management.Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
https://reachmd.com/programs/cme/data-driving-recent-guideline-updates-in-neoadjuvant-therapy-for-resectable-melanoma/36322/Explore guideline-based treatment strategies and clinical data to optimize guideline-concordant care for patients with melanoma in the neoadjuvant, adjuvant, and metastatic settings.Surgical Evaluation and Treatment for Genetic Epilepsies
https://reachmd.com/diseases-diagnoses/epilepsy-seizures/surgical-evaluation-and-treatment-for-genetic-epilepsies/32053/Genetic diagnosis can be useful in guiding surgical options for genetic epilepsies.Optimizing the Care and Quality of Life for Patients with ADPKD – Part 3: Management
https://reachmd.com/programs/cme/optimizing-the-care-and-quality-of-life-for-patients-with-adpkd-part-3-management/12679/Once a patient is diagnosed with autosomal dominant polycystic kidney disease, how can we manage them?Another COVID-19 Vaccine Milestone Reached
https://reachmd.com/programs/the-drug-report/another-covid-19-vaccine-milestone-reached/12119/A second COVID-19 vaccination EUA approval marks another milestone in the global battle against the COVID-19 pandemic.Additional Safey Data From TROPION-Breast02 and Study Design of TROPION-Breast06
https://reachmd.com/clinical-practice/oncology-hematology/additional-safey-data-from-tropion-breast02-and-study-design-of-tropion-breast06/49125/Learn how TROPION-Breast02 and TROPION-Breast06 are shaping the role of Dato-DXd in mTNBC and chemo-naïve HR+/HER2- mBC, respectively.Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
https://reachmd.com/programs/cme/comparing-first-line-trop2-directed-adcs-in-metastatic-tnbc-latest-clinical-evidence/60633/Explore how first-line TROP2-directed ADCs are reshaping metastatic TNBC care, with evidence-based treatment selection and proactive toxicity management.